Dr. Jean-Pierre Ayoub discusses studies from ESMO 2025 that could soon impact breast oncology practice, including TROPION-Breast02 and ASCENT-03 for metastatic TNBC, along with HER2-positive updates from DESTINY-Breast11 and DESTINY-Breast05 with T-DXd therapy.
